Structure and physiological functions of the human peroxisome proliferator-activated receptor γ

被引:118
作者
Zieleniak, Andrzej [1 ]
Wojcik, Marzena [1 ]
Wozniak, Lucyna A. [1 ]
机构
[1] Med Univ Lodz, Dept Biol Struct, Chair Gen Endocrinol, PL-90752 Lodz, Poland
关键词
PPAR-gamma; adipogenesis; insulin resistance; thiazolidinediones;
D O I
10.1007/s00005-008-0037-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily. To date, three different PPAR isotypes, namely PPAR-alpha, -delta, and -gamma, have been identified in vertebrates and have distinct patterns of tissue distribution. Like all nuclear receptors, the human PPAR-gamma (hPPAR-gamma) is characterized by a modular structure composed of an N-terminal A/B domain, a DNA-binding domain with two zinc fingers (C domain), a D domain, and a C-terminal ligand-binding domain (E/F domain). Human PPAR-gamma exists in two protein isoforms, hPPAR-gamma 1 and -gamma 2, with different lengths of the N-terminal. The hPPAR-gamma 2 isoform is predominantly expressed in adipose tissue, whereas hPPAR-gamma 1 is relatively widely expressed. Human PPAR-gamma plays a critical physiological role as a central transcriptional regulator of both adipogenic and lipogenic programs. Its transcriptional activity is induced by the binding of endogenous and synthetic lipophilic ligands, which has led to the determination of many roles for PPAR-gamma in pathological states such as type 2 diabetes, atherosclerosis, inflammation, and cancer. Of the synthetic ligands, the thiazolidinedione class of insulin-sensitizing drugs (ciglitazone, pioglitazone, troglitazone, rosiglitazone) is employed clinically in patients with type 2 diabetes.
引用
收藏
页码:331 / 345
页数:15
相关论文
共 149 条
[1]   Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site [J].
Adams, M ;
Reginato, MJ ;
Shao, DL ;
Lazar, MA ;
Chatterjee, VK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) :5128-5132
[2]   A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy [J].
Agarwal, AK ;
Garg, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :408-411
[3]   The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].
Altshuler, D ;
Hirschhorn, JN ;
Klannemark, M ;
Lindgren, CM ;
Vohl, MC ;
Nemesh, J ;
Lane, CR ;
Schaffner, SF ;
Bolk, S ;
Brewer, C ;
Tuomi, T ;
Gaudet, D ;
Hudson, TJ ;
Daly, M ;
Groop, L ;
Lander, ES .
NATURE GENETICS, 2000, 26 (01) :76-80
[4]   Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells [J].
Arakawa, K ;
Ishihara, T ;
Aoto, M ;
Inamasu, M ;
Saito, A ;
Ikezawa, K .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (03) :429-436
[5]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[6]   Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients [J].
Auboeuf, D ;
Rieusset, J ;
Fajas, L ;
Vallier, P ;
Frering, V ;
Riou, JP ;
Staels, P ;
Auwerx, J ;
Laville, M ;
Vidal, H .
DIABETES, 1997, 46 (08) :1319-1327
[7]   PPARγ, the ultimate thrifty gene [J].
Auwerx, J .
DIABETOLOGIA, 1999, 42 (09) :1033-1049
[8]   PPARγ is required for placental, cardiac, and adipose tissue development [J].
Barak, Y ;
Nelson, MC ;
Ong, ES ;
Jones, YZ ;
Ruiz-Lozano, P ;
Chien, KR ;
Koder, A ;
Evans, RM .
MOLECULAR CELL, 1999, 4 (04) :585-595
[9]   PPAR signaling in the control of cardiac energy metabolism [J].
Barger, PM ;
Kelly, DP .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (06) :238-245
[10]   Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].
Barroso, I ;
Gurnell, M ;
Crowley, VEF ;
Agostini, M ;
Schwabe, JW ;
Soos, MA ;
Maslen, GL ;
Williams, TDM ;
Lewis, H ;
Schafer, AJ ;
Chatterjee, VKK ;
O'Rahilly, S .
NATURE, 1999, 402 (6764) :880-883